Prospecting for an HIV vaccine

D. M. Brett-Major*, T. A. Crowell, N. L. Michael

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Human immunodeficiency virus (HIV) sets several challenges for the development of a preventative HIV vaccine. Predictable, protective natural immunity against HIV does not occur and so unlike most other diseases for which vaccines exist, there are few guideposts from natural infection. Nonetheless, six vaccine efficacy trials have occurred. One in particular, the Thai trial called RV144, showed partial protective efficacy and potential ways ahead to a better vaccine approach. This coupled with other lessons from studies of acute infections as well as an increasingly complex knowledge of HIV-related vaccine immunology bring hope that a vaccine solution might be reached for this pervasive and deadly pandemic.

Original languageEnglish
Article number6
JournalTropical Diseases, Travel Medicine and Vaccines
Issue number1
StatePublished - 24 Mar 2017
Externally publishedYes


  • Human immunodeficiency virus vaccine protective efficacy immunology review


Dive into the research topics of 'Prospecting for an HIV vaccine'. Together they form a unique fingerprint.

Cite this